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Drug discovery and the BBBTo systematically study the pharmacodynamics of a
CNS drug early in the development process, we devel-
oped and validated a battery of drug-sensitive CNS
tests, which we call NeuroCart. Using this test battery,
data-intensive phase 1 studies in healthy subjects can
be performed to demonstrate the specific, time- and
dose-dependent, neurophysiological and/or neuropsy-
chological effects of a compound, thereby confirming
whether the test compound reaches its intended target
in the CNS – or does not reach its intended target. We
use this test battery to demonstrate that a compound
passes the blood–brain barrier.
Introduction
To systematically study the pharmacodynamics of a CNS drug
early in the development process, we developed and validat-
ed a battery of drug-sensitive CNS tests, which we call Neu-
roCart. Using this test battery, data-intensive phase 1 studies
in healthy subjects can be performed to demonstrate the
specific, time- and dose-dependent, neurophysiological
and/or neuropsychological effects of a compound, thereby
confirming whether the test compound reaches its intended
target in the CNS – or does not reach its intended target. We
use this test battery to demonstrate that a compound passes
the blood–brain barrier. The battery can also be used to
compare the profiles of CNS active drugs with respect to their*Corresponding author: G.J. Groeneveld (ggroeneveld@chdr.nl)
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effects on the range of tests in the NeuroCart, and allows
comparison of new compounds with an innovative mecha-
nism of action to established drugs that were previously
profiled.
Whether a newly developed drug ultimately reaches the
market depends largely on its targeted therapeutic area. Drugs
that target the CNS generally have the lowest likelihood of
reaching the market due to a variety of factors, including the
complexity of the target organ (the brain), the high probabili-
ty of causing CNS side effects, and the requirement of the CNS
drug to cross the blood–brain barrier (BBB) [1]. Among these
factors, it is fair to say that BBB penetration is one of the most
significant factor in terms of restricting the development of
new CNS drugs [2]. Many CNS drugs failed to reach the market
because of their inability to cross the BBB; however, the worst-
case scenario occurs when this is discovered only at a very late
stage in the drug’s development, after years of research and
huge sums have been invested. For example, the gamma
secretase modulator flurbiprofen (tarenflurbil) was being de-
veloped for Alzheimer’s disease, but development was termi-
nated after a phase III study failed. Only then was it
determined that the drug’s mechanism of action was ineffec-
tive at putative therapeutic concentrations because it did not
cross the BBB [3]. Another example is Gavestinel (GV150526),
a glycine antagonist that targets the N-methyl-D-aspartateticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Although several phase III clinical trials were performed, the
drug failed, most likely because it did not cross the BBB [1].
Failure in phase III of a drug’s development can be ex-
tremely expensive and frustrating; therefore, pharmaceutical
companies have an urgent need for predicting whether a drug
is likely to pass phase III testing as early as possible in the
development process. In 1998, the US Food and Drug Ad-
ministration (FDA) and the European Medicines Agency
(EMA) established a guideline regarding the general aspects
of clinical trials; the guideline states that ‘The essence of
rational drug development is to ask important questions
and answer them with appropriate studies’ [4]. Consistent
with this goal, we developed a question-based system to
design a structured approach for evaluating new medicines.
Question-based drug development uses a logical progression
of questions [5]. In this process, the first question is whether a
new drug reaches its intended site of action. In the case of a
CNS drug, this translates to the following question: ‘Does this
compound cross the BBB?’.
There are several ways to test whether a compound crosses
the BBB. For example, microdialysis, autoradiography, and
even whole-brain homogenization can be used in animal
models. Because these methods are not feasible in human
subjects, clinical trials use other techniques such as positron
emission tomography (PET), single-photon emission com-
puterized tomography (SPECT) and cerebrospinal fluid
(CSF) sampling to indirectly measure BBB penetration.
Using PET, researchers can measure the localization of the
radiolabeled drug in the brain; an improved technique mea-
sures displacement of a validated PET tracer from a receptor,
which can provide direct evidence of both BBB penetration
and binding to the relevant receptor. This approach requires
either a validated PET tracer for a specific receptor (which is
often not available in the case of a novel drug) or develop-
ment of a radiolabeled drug (which requires changing the
molecule’s structure and the need for new preclinical toxi-
cology studies before the human PET study can be per-
formed). Moreover, PET studies (i) cannot be combined
with first-in-human drug testing, (ii) are expensive to per-
form, and (iii) it may not be straightforward to determine the
optimal binding range for compounds with complex or new
action mechanisms [6]. SPECT is a less expensive alternative
to PET, but it is also more difficult to quantify reliably enough
for predictions of drug concentrations in the CNS [7]. Lastly,
although CSF sampling provides only indirect evidence of
BBB penetration (as the blood-CSF barrier is not identical to
the BBB), it is generally believed that a compound that
reaches the CSF will also – at least to some extent – reach
the brain. Unfortunately, however, obtaining a CSF sample
by lumbar puncture or spinal catheterization can be burden-
some to some subjects, causing post-puncture headache in
5–50% of cases, and the test cannot definitively demonstrate28 www.drugdiscoverytoday.comthat pharmacologically active levels of the compound reach
the target tissue.
The penetration of a drug across the BBB is characterized by
changes in brain concentrations and effects over time [6].
Consequently, establishing a concentration–effect relation-
ship between the test compound and CNS function can be
regarded as evidence of BBB penetration. A robust concen-
tration–effect relationship is clear evidence of pharmacologi-
cal activity in the CNS. Given that most modern drugs are
characterized by high specificity for a single pharmacological
target (for example, a specific receptor), any effects that are
closely related to the plasma concentrations of such a drug are
likely due to the compound’s specific mechanism of action.
Thus, effects that show a pharmacokinetics/pharmacody-
namics (PK/PD) relationship provide clear evidence of phar-
macological activity. This activity can also be expected to
underlie the drug’s therapeutic action, although not neces-
sarily in the same physiological system and/or anatomical
brain region. To cover the entire range of drug action, in-
cluding the effects that are most closely associated with
therapeutic activity, test batteries that measure a broad range
of functions should be used for measuring pharmacodynam-
ics effects throughout the CNS.
A CNS test battery: NeuroCart
Based on experience and the published literature, we selected
pharmacodynamics tests that have a high sensitivity for
pharmacological effects and robust reproducibility using a
wide range of compounds. Indeed, the full battery of tests
covers an extremely wide range of relevant domains regard-
ing CNS function. For the purposes of neuropharmacology
studies, the following six domains were defined: executive
function, attention, memory, visuomotor function, motor
skills, and subjective drug effects. To be included in the test
battery, each test needed to be confirmed as a reliable bio-
marker for either intended or unintended pharmacological
effects in one or more of these domains. To differentiate
between a pharmacological effect on the CNS and nonspecific
effects caused by peripheral activity, a clear concentration–
effect relationship was required. Each biomarker (i.e., test)
must also have a consistent response across studies and drugs.
Finally, the biomarker must have a clear response to a thera-
peutic dose, and a plausible relationship must be established
between the biomarker, pharmacology, and pathogenesis.
Armed with these criteria, we searched the literature for
optimal tests that have been used for various compounds
that were known to affect CNS function. Given the large
number of tests, and given the wide variation in the way the
tests were performed, a formal meta-analysis was not feasible.
However, we were able to identify tests that consistently
showed a significant concentration-dependent effect with a
given class of drug. We therefore performed several system-
atic literature reviews, which enabled us to evaluate in
Vol. 20, 2016 Drug Discovery Today: Technologies | Drug discovery and the BBBhealthy volunteers the sensitivity of pharmacodynamics tests
using prototype drugs such as neuroleptics, benzodiazepines,
selective serotonin re-uptake inhibitors (SSRIs), ethanol, 3,4-
methylenedioxy-methamphetamine (MDMA, or ecstasy),
and cannabis [8–14]. With many such neuropharmacologi-
cally active substances, one or more parameters showed high
sensitivity for a pharmacological effect in healthy subjects.
The characteristics of pharmacodynamics tests can play a
crucial role in determining whether a drug produces an
observable effect. Therefore, a pharmacodynamics test must
be validated and a reference drug must show a consistent,
reproducible effect at relevant (i.e., therapeutic) doses. In
addition, a dose–response effect must be measured. More-
over, the test must be sensitive to the effects that are
intended to be measured, and this is particularly important
in the early stages of drug development, which typically
involve relatively small numbers of healthy volunteers. Al-
though measuring the PK/PD relationship can provide evi-
dence of pharmacological action, this relationship can only
be determined by repeatedly measuring the drug’s effects
while measuring its plasma concentration. Unfortunately,
however, many CNS tests are time-consuming, are not adapt-
able, and/or have learning effects. Thus, in order to be
suitable for our purposes, pharmacological biomarkers must
be both brief and repeatable.
Studies that require repetitive use of a CNS test battery can
be incorporated in the design of relatively simple studies
and can include fundamental phase I objectives related to
pharmacokinetics, safety, and tolerability. Moreover, do-
main-specific CNS effects and pharmacological endpoints
can be incorporated easily into the study design. Important-
ly, CNS tests that are easy and relatively simply to perform
interfere only minimally with other study requirements,
allowing pharmacokinetics samples to be taken frequently
and as needed while satisfying the need to monitor poten-
tial adverse events. Needless to say, studies that include
pharmacodynamics testing in early drug development –
particularly studies that investigate CNS effects – should
have a double-blind, randomized, placebo-controlled de-
sign. Experience in recent decades has shown that adequate
biomarkers can detect the effects of most drugs that affect
CNS activity.
Some CNS drugs may not have significant and/or measur-
able effects in healthy subjects. Compounds that are designed
to improve cognition are a good example of this issue, as
improving cognition is extremely difficult in healthy subjects
with relatively normal cognitive capability. In these cases,
inducing a pharmacological challenge in healthy subjects
may be used to reveal the drug’s effects. For example, the
muscarinic acetylcholine receptor antagonist scopolamine
can reduce cognitive function in healthy subjects, thereby
establishing a baseline for testing the effects of newly devel-
oped cognition-enhancing compounds [15].On the other hand, an increasing number of compounds are
designed to exert their effect on perturbed pharmacological
systems without affecting the brain during normal function.
In theory, such neuromodulatory drugs have a clear advan-
tage: their activity is specific to the pathophysiological condi-
tion, and their effects – including any adverse effects – will
resolve when the healthy physiological state returns. However,
this neuromodulatory activity is difficult to detect in healthy
subjects. For example, a single dose of a cannabinoid antago-
nist has no specific effect in healthy subjects, which can
complicate the researcher’s ability to predict pharmacological-
ly active drug levels in early phases of development. In such
cases, modulatory drug’s that target perturb CNS function
temporarily can be administered. In the above-mentioned case
of cannabinoids, the cannabinoid system can be activated by
administering a cannabinoid agonist such as tetrahydrocan-
nabinol (THC), which produces effects that can be easily
measured in healthy subjects. These effects can be suppressed
with cannabinoid receptor antagonists in a concentration-
related manner [16]. Another example includes using the
serotonergic challenge to detect the effects of SSRIs [17] (which
are also typically difficult to measure reliably [11,13]). Of
course, these challenge tests are more complicated than per-
forming test batteries of pharmacological biomarkers, and
they require extensive validation. However, with adequate
preparation, challenge tests can often provide compelling
evidence of the pharmacological activity of neuromodulators
and/or receptor antagonists and BBB penetration in early
phases of development.
The NeuroCart
The NeuroCart CNS test battery contains the following core
tests: saccadic eye movement, smooth pursuit eye movement,
the Bowdle visual analog scale (VAS), the Bond and Lader VAS,
body sway, adaptive tracking, visual verbal learning, and
quantitative electroencephalography (qEEG) (Table 1).
Saccadic eye movements are extremely sensitive to a wide
range of drugs that act as depressants on the CNS [18,19]. A
distinct drug-sensitive eye movement system is smooth pur-
suit eye movements. This test has been validated at CHDR
[20] and is based on the work of others [21].
A series of VASs as originally described by Norris [22] have
been used previously to quantify the subjective effects of
benzodiazepines [23]. From the original set of 15 scales, three
composite factors – corresponding to alertness, mood, and
calmness – were derived as described by Bond and Lader [24].
These factors are used to quantify the subjective effects of
CNS drugs.
The body sway meter measures body movement in a single
plane, thus providing a measure of postural stability. This
method has been used extensively to demonstrate drug-in-
duced postural instability [25].www.drugdiscoverytoday.com 29
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Table 1. The tests included in the NeuroCart test battery and their related CNS domains [31].
NeuroCart test Targeted function Related CNS areas
Saccadic eye movement Neurophysiologic function Superior colliculus, substantia nigra, amygdala
Smooth pursuit Neurophysiologic function Midbrain
Adaptive tracking Visuomotor coordination Neocortex, basal nuclei, brain stem, cerebellum
Body sway Balance Cerebellum, brain stem
Visual verbal learning test (VVLT) Memory Hippocampus
VAS Bond and Lader Alertness, mood, calmness Cortex, prefrontal cortex
VAS Bowdle Feeling high, internal and external perception Cortex, prefrontal cortex, amygdala
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Figure 1. Forest plots summarizing the effects of depressant compounds on the indicated tests. On the x-axis is plotted the least square mean estimate of
the difference from placebo (95% CI) for saccadic peak velocity, smooth pursuit, body sway, and adaptive tracking. Each drug/compound is color-coded by
drug class. The vertical dashed lines are reference lines used to assess significance and effect size.
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Vol. 20, 2016 Drug Discovery Today: Technologies | Drug discovery and the BBBThe adaptive tracking test is based on specifications of
Borland and Nicholson [26]. The adaptive tracking test
provides a measure of visuomotor coordination and is
extremely sensitive to a variety of psychoactive drugs
and compounds that affect arousal and/or vigilance
[18,25,27].
The visual verbal learning test measures various compo-
nents of learning, including the acquisition, consolidation,
storage, and retrieval of memories [28]. When administered
to healthy subjects, the 30-word learning test does not have a
ceiling effect, and it can reveal CNS effects induced by a
variety of compounds, including benzodiazepines [29], can-
nabinoids [14], and antipsychotics [9].
EEG is one of the most widely used biomarkers in drug
research, because of its preclinical and clinical applicabilityPeripheral oxygen saturation 80%
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Figure 2. Forest plots summarizing the effects of depressants, antidepressants,
adaptive tracking. See Fig. 1 for details.and its sensitivity to a wide range of conditions that affect CNS
activity [30]. With the NeuroCart, EEG recordings are per-
formed using silver chloride electrodes fixed with collodion
adhesive at the Fz, Cz, Pz, and Oz positions; the same common
ground electrode is used for the EEG recordings and the eye
movement measurements.
Profiling CNS drugs using the NeuroCart
As discussed above, tests that measure the pharmacody-
namics effects of drugs on CNS functions can be used to
provide evidence that the drug has crossed the BBB and
entered the brain. In particular, establishing a dose-effect
relationship can provide compelling evidence that the
test compound’s effect is in the CNS (and – by extension
– that the test compound has penetrated the BBB). The–
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 and stimulants on saccadic peak velocity, smooth pursuit, body sway, and
www.drugdiscoverytoday.com 31
Drug Discovery Today: Technologies | Drug discovery and the BBB Vol. 20, 2016
During night
Sleep deprivation
Bretazenil 0.5mg SL
AZD6280 40mg PO
AZD7325 10mg PO
SL-651.498 25mg PO
L-830982 2mg PO
L-830409 0.75mg PO
Diazepam 10mg PO
Lorazepam 2mg PO
Midazolam 5mg IN
Midazolam 2.5mg IV
Midazolam 0.1mg/kg IV
Nitrazepam 5mg PO
Nitrazepam 5mg PO (Jap)
Alprazolam 1mg PO
Ro 486791 10mg
Ro 488684 10mg
Temazepam 629ng/mL IV
Temazepam 629ng/mL IV Fast
Temazepam 20mg PO
Zolpidem 20mg PO
Ethanol 0.6g/L TCI
Ethanol 0.6g/L IV
Ethanol 20g PO
Mecamylamine 20mg IV
Scopolamine 0.5mg IV
GSK598809 175mg PO
Risperidone 2mg PO
JNJ37822681 20mg PO
Sulpiride 400mg PO
Haloperidol 3mg PO
Olanzapine 10mg PO
SB742457 50mg PO
L Y2624803 6mg PO
Diphenhydramine 50mg PO
R231857 320mg PO
R213129 30mg PO
Org 25935 0.5mg PO
Almorexant 1000mg PO
Namisol 8mg PO
Org 28611 10mcg/kg IV
THC 20mg IH
Org 26828 6mcg/kg IV
ASP3652 1800mg PO
Galantamine 20mg PO
Donepezil 10mg PO
RO5114698 50mg PO
CEP 26401 125 mcg PO
5HTP 200mg PO
Dexfenfluramine 0.5mg/kg PO
Amitriptyline 50mg PO
Citalopram 20mg PO
Sertraline 75mg PO
mCPP 0.5mg/kg PO
mCPP 0.1mg/kg IV
Rizatriptan 10mg PO
Sumatriptan 50mg PO
Lisuride 0.2mg PO
Modafinil 200 mg PO
Ketamine 240mg/L IV
Ketamine 120mg/L IV
Aprepitant 160mg PO
Talnetant 200mg PO
Peripheral oxygen saturation 80%
Peripheral oxygen saturation 90%
Pregabaline 200mg PO
GPI1 750mg PO
GPI5693 1125mg PO
Caffeine 60mg PO
Sa
cca
dic
 pe
ak 
vel
oc
city
 
Sm
oo
th 
pu
rsu
it
Bo
dy
 
sw
ay
Ad
ap
tive
 
tra
cki
ng
VA
S a
ler
tne
ss
VA
S e
xte
rna
l
VA
S i
nte
rna
l
VA
S f
ee
lin
g h
igh
EE
G A
lph
a p
ow
er
 Fz
Cz
EE
G A
lph
a p
ow
er
 Pz
Oz
EE
G B
eta
 po
we
r F
zC
z
EE
G B
eta
 po
we
r P
zO
z
EE
G 
De
lta
 po
we
r P
zO
z
EE
G T
he
ta 
po
we
r P
zO
z
EE
G T
he
ta 
po
we
r F
zC
z
EE
G D
elta
 po
we
r F
zC
z
NA
2
1.5
1
0.5
0
–0.5
–1
–1.5
–2
↓
↑
Drug Discovery Today: Technologies
Figure 3. Heat plot depicting the ratios between the measured drug effects and the ‘minimal detectable effect sizes’. ‘Warmer’ colors indicate an increase,
and ‘colder’ colors indicate a decrease of activity. Data that are not available (NA) are plotted in white.
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Vol. 20, 2016 Drug Discovery Today: Technologies | Drug discovery and the BBBNeuroCart is a multi-dimension CNS test battery that was
created using information obtained from an extensive lit-
erature reviews [8–14]. An important advantage of the
approach used to develop the NeuroCart is that it led to
a core battery of tests that have not changed significantly
over the years, allowing the creation of a relatively static
panel of cognitive, psychomotor, subjective drug effect,
and neurophysiological measurements measured using a wide
variety of drugs and drug classes. Using this comprehensive
panel, researchers can define profiles of drug classes – or even
individual drugs – with respect to their effect on various
NeuroCart tests. In a recent meta-analysis, we analyzed the
pharmacodynamics profiles of a range of compounds, includ-
ing antidepressants, stimulants, and CNS depressant agents;
the data were obtained from 38 studies that used various CNS
active drugs. The results of this meta-analysis are summarized
in Figs 1 and 2. Specifically, the effect profiles of both the
registered drugs and the compounds under development are
shown for four NeuroCart tests; these tests were chosen be-
cause they were the most informative with respect to the
stimulant and depressant properties of CNS active com-
pounds. Figure 3 shows the effects of the same 38 compounds
measured using all of NeuroCart’s tests, displayed as a heat
plot. This type of plot can also be used to visually determine
the pharmacodynamics profile for a new CNS active com-
pound. A direct comparison between two pharmacologically
related compounds can also be displayed as a spider web plot,
clearly illustrating the differences in profiles between com-
pounds, as well as the dose-dependent effects of the drug being
developed.
In summary, clear evidence showing that a compound can
penetrate the BBB can be obtained using the NeuroCart test
battery. Moreover, the NeuroCart can use to create a unique
‘fingerprint’ (profile) with respect to both desired and unde-
sired CNS effects. This versatile research tool can be included
in any phase I drug study, which typically covers the widest
range of doses and concentrations in the entire drug develop-
ment program. Consequently, for drugs with established
modes of action, the NeuroCart can already provide indica-
tions for pharmacological activity, therapeutically relevant
concentration ranges, and BBB-penetration, during the first
administration in man [32,33]. Equally importantly, the ab-
sence of CNS-effects for these compounds is a certain sign that
the drug did not reach the brain. For compounds with novel
mechanisms of action, demonstration of concentration-de-
pendent CNS-effects will provide similar confidence that the
drug penetrated the brain. However, the absence of such
effects may be related to limitations of the NeuroCart to detect
the novel mechanism, and further studies with repeated
dosing or other methods (CSF-sampling, PET) may still be
warranted. With these considerations, the proper use of CNS-
measurements in early drug development can provide impor-
tant information that can be used to make a go/no-go decisionregarding further development, as well as to guide the deci-
sion-making process regarding the dosage range to be used in
phase II studies, determining a therapeutic window, and even
identifying the target population.
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